Vertex Pharmaceuticals has a total of 12016 patents globally, out of which 5124 have been granted. Of these 12016 patents, more than 37% patents are active. United States of America is where Vertex Pharmaceuticals has filed the maximum number of patents, followed by Europe and Japan. Parallelly, USA seems to be the main focused R&D center and also is the origin country of Vertex Pharmaceuticals.
Vertex Pharmaceuticals was founded in 1989 by Joshua Boger. Vertex Pharmaceuticals discovers, develops, and commercializes pharmaceutical products. The Company develops drugs for the treatment of cystic fibrosis, cancer, inflammatory bowel, autoimmune disease, and neurological disorders. Vertex Pharmaceuticals serves healthcare sector worldwide. As of May 2022, Vertex Pharmaceuticals has a market cap of $69.57 Billion.
Read about some of the most popular patents of Vertex Pharmaceuticals which have been covered by us in this article and also you can find Vertex Pharmaceuticals patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Vertex Pharmaceuticals patent portfolio.
How many patents does the Founder and CEO of Vertex Pharmaceuticals have?
The Founder Joshua Boger have 126 patents and the CEO Reshma Kewalramani have 10 patents.
How many patents does Vertex Pharmaceuticals have?
Vertex Pharmaceuticals has a total of 12016 patents globally. These patents belong to 1429 unique patent families. Out of 12016 patents, 4501 patents are active.
How Many Patents did Vertex Pharmaceuticals File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Vertex Pharmaceuticals Applications Filed | Vertex Pharmaceuticals Patents Granted |
| 2011 | 669 | 340 |
| 2012 | 614 | 413 |
| 2013 | 522 | 397 |
| 2014 | 617 | 353 |
| 2015 | 304 | 259 |
| 2016 | 261 | 256 |
| 2017 | 228 | 254 |
| 2018 | 275 | 298 |
| 2019 | 292 | 230 |
| 2020 | 231 | 231 |
| 2021 | 166 | 295 |
| 2022 | 8 | 56 |
Explore the top-performing drugs that dominate the Pharmaceutical Industry
| Patent Number | Company | Product | Brand | Revenue | Patent Expiry Date |
| US9174975 | Sumitomo Pharma | Lurasidone Hydrochloride | Latuda | $1.75B | Jun-26 |
| US7612199 | Alfasigma | Rifaximin | Xifaxan | $1.64B | Nov-24 |
| US7902206 | Alfasigma | Rifaximin | Xifaxan | $1.64B | Nov-24 |
| US8158644 | Alfasigma | Rifaximin | Xifaxan | $1.64B | Nov-24 |
| US7371727 | Ironwood Pharma | Linaclotide | Linzess | $1.00B | Mar-25 |
Want to know which drugs are making over $1 Billion annually?
How many Vertex Pharmaceuticals patents are Alive/Dead?
Worldwide Patents
How Many Patents did Vertex Pharmaceuticals File in Different Countries?
Countries in which Vertex Pharmaceuticals Filed Patents
| Country | Patents |
| United States Of America | 1466 |
| Europe | 867 |
| Japan | 840 |
| Australia | 682 |
| India | 630 |
| Hong Kong (S.A.R.) | 584 |
| Canada | 522 |
| China | 512 |
| Germany | 385 |
| Mexico | 359 |
| Israel | 355 |
| Korea (South) | 335 |
| New Zealand | 315 |
| Spain | 283 |
| Singapore | 252 |
| Russia | 239 |
| Taiwan | 226 |
| South Africa | 198 |
| Austria | 192 |
| Brazil | 163 |
| Argentina | 160 |
| Denmark | 150 |
| Portugal | 140 |
| Poland | 137 |
| Norway | 127 |
| Slovenia | 113 |
| Chile | 86 |
| Hungary | 76 |
| Croatia | 73 |
| Cyprus | 65 |
| Serbia | 60 |
| Lithuania | 57 |
| Eurasia | 56 |
| Ukraine | 52 |
| Malaysia | 50 |
| Albania | 44 |
| Indonesia | 42 |
| Uruguay | 36 |
| Viet Nam | 35 |
| Peru | 35 |
| Africa | 30 |
| Turkey | 24 |
| Philippines | 24 |
| Czech Republic | 24 |
| Slovakia | 23 |
| Georgia | 22 |
| Montenegro | 17 |
| Colombia | 17 |
| Bulgaria | 14 |
| Ecuador | 14 |
| Former Yugoslav Republic of Macedonia | 9 |
| Iceland | 9 |
| Macao | 9 |
| Estonia | 8 |
| Luxembourg | 6 |
| Panama | 6 |
| Costa Rica | 6 |
| Morocco | 6 |
| San Marino | 5 |
| Dominican Republic | 4 |
| Romania | 4 |
| Jordan | 4 |
| Kenya | 3 |
| Netherlands | 3 |
| Ireland | 3 |
| Finland | 3 |
| Tunisia | 2 |
| Republic of Moldova | 2 |
| Brunei | 2 |
| Yugoslavia/Serbia and Montenegro | 1 |
| Saudi Arabia | 1 |
| Kyrgyzstan | 1 |
| Nicaragua | 1 |
| Algeria | 1 |
Where are the Research Centers of Vertex Pharmaceuticals Patents Located?
10 Best Vertex Pharmaceuticals Patents
WO2005095400A1 is the most popular patent in the Vertex Pharmaceuticals portfolio. It has received 506 citations so far from companies like Incyte Corporation, Almirall Sa and Biomea Fusion Llc.
Below is the list of 10 most cited patents of Vertex Pharmaceuticals:
| Publication Number | Citation Count |
| WO2005095400A1 | 506 |
| US6344465B1 | 411 |
| US6498178B2 | 405 |
| WO2006127587A1 | 361 |
| WO2007056341A1 | 355 |
| WO2002022601A1 | 351 |
| WO2004111014A1 | 319 |
| WO2005075435A1 | 314 |
| WO2004072063A1 | 314 |
| US6686193B2 | 269 |
Which Companies are using Vertex Pharmaceuticals Patents to Advance their Research?
If patents or patents from a particular technology area of a company receive a lot of citations, it implies that the technology is being followed and incrementally innovated by the citing companies. It also indicates that citing companies are working on similar and closely related technologies.
The top citing companies in the Vertex Pharmaceuticals patent portfolio are Biomed Valley Discoveries Inc, Merck Sharp & Dohme Corp and Abbvie Inc.
List of the top forward citing Companies –
| Company | Number of Patents |
| Biomed Valley Discoveries Inc | 9 |
| Merck Sharp & Dohme Corp | 8 |
| Abbvie Inc | 7 |
| Deep Science Llc | 5 |
| Novartis | 4 |
| Gilead Pharmasset Llc | 4 |
| Concert Pharmaceuticals | 3 |
| Acea Biosciences Inc | 3 |
| Arqule Inc | 3 |
| Otsuka Pharmaceutical Co Ltd | 3 |
Count of 102 and 103 Type Rejections based on Vertex Pharmaceuticals Patents
Top Vertex Pharmaceuticals Patents used in Rejecting Most Patent Applications
| Patent Number | Count of Rejected Applications |
| US7361492B2 | 16 |
| US6686193B2 | 13 |
| US7354939B2 | 9 |
| US20100011610A1 | 6 |
| US8431615B2 | 6 |
| US7219545B2 | 6 |
| US20100256184A1 | 5 |
| US6969449B2 | 4 |
| US7495014B2 | 3 |
| US7615356B2 | 3 |
| US7547794B2 | 3 |
| US20070218138A1 | 3 |
| US20070225297A1 | 3 |
| US6638926B2 | 3 |
| US7498166B2 | 3 |
What Percentage of Vertex Pharmaceuticals US Patent Applications were Granted?
Vertex Pharmaceuticals (Excluding its subsidiaries) has filed 1667 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 1067 have been granted leading to a grant rate of 76.3%.
Below are the key stats of Vertex Pharmaceuticals patent prosecution at the USPTO.
Which Law Firms Filed Most US Patents for Vertex Pharmaceuticals?
| Law Firm | Total Applications | Success Rate |
| Vertex Pharmaceuticals Incorporated | 811 | 73.52% |
| Jonathan P O Brien PhD Vpi | 242 | 53.72% |
| Haley Guiliano Llp | 132 | 88.19% |
| Dechert Llp | 52 | 95.56% |
| Barnes & Thornburg Llp | 39 | 83.87% |
| Knobbe Martens Olson & Bear Llp | 33 | 100.00% |
| Life Technologies Corporation | 21 | 80.95% |
| Troutman Pepper Hamilton Sanders Llp | 18 | 77.78% |
| Lisa A Dixon | 17 | 100.00% |
| Nandakumar Govindaswamy | 15 | 33.33% |
EXCLUSIVE INSIGHTS COMING SOON!
What are Vertex Pharmaceuticals key innovation segments?